Company intelligence / Profile preview

Harpoon Therapeutics

South San Francisco, California, United Statesharpoontx.com ↗

Ownership: Public · MRK
Development stage: Phase 2

Overview

Harpoon Therapeutics has shown clinical activity in multiple programs, including a confirmed partial response in the HPN424 trial for metastatic castration-resistant prostate cancer. Their HPN217 program for multiple myeloma has demonstrated continued evidence of clinical activity and a tolerable safety profile in heavily pre-treated patients as of October 2022. The company has multiple ongoing clinical trials across its pipeline.[6][7][9]

Therapeutic areas: Oncology
Modalities: T cell engagersTriTAC platformProTriTAC platformTriTAC-XR platform
Industry: Biotech

Drug pipeline

3 assets

HPN328

Phase 1/2

Indications: Small cell lung cancer, Neuroendocrine tumors

2 more assets in the full pipeline.

Partnerships

Merck

Beyond the preview

Go deeper on Harpoon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harpoon Therapeutics.